Cytomegalovirus Clinical Trials | A Drug Pipeline Analysis Report 2023 | Key Companies- Moderna, and others

DelveInsight’s ‘Cytomegalovirus Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Cytomegalovirus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cytomegalovirus pipeline domain.

Key Takeaways from the Cytomegalovirus Pipeline Report

• Over 20+ Cytomegalovirus pipeline therapies are in various stages of development, and their anticipated acceptance in the Cytomegalovirus market would significantly increase market revenue. 
• Leading Cytomegalovirus companies developing novel drug candidates to improve the Cytomegalovirus treatment landscape include Moderna, and others.
• Promising Cytomegalovirus pipeline therapies in various stages of development include mRNA-1647,and others.

Cytomegalovirus Overview

Cytomegalovirus (CMV) is a wide-spread virus, with manifestations ranging from asymptomatic to severe end-organ dysfunction in immunocompromised patients with congenital CMV disease. Human cytomegalovirus is a member of the viral family known as herpesviruses, Herpesviridae, or human herpesvirus-5 (HHV-5). Human cytomegalovirus infections commonly are associated with the salivary glands. CMV infection may be asymptomatic in healthy people, but they can be life-threatening in an immunocompromised patient.

Cytomegalovirus Pipeline Analysis: Drug Profile

mRNA-1647: Moderna

mRNA-1647 includes six mRNAs encoding two antigens in one vaccine and is developed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex, and one mRNA encodes the glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is vital for CMV entry into a majority of cells, including epithelial cells, while gB is essential for entry into all susceptible cells, including fibroblasts. A vaccine that develops an immune response against both pentamer and gB has the potential to prohibit CMV entry into a range of target cell types and thus inhibit primary and congenital infections.

Discover more about the emerging Cytomegalovirus drugs @ Cytomegalovirus Treatment Drugs

Cytomegalovirus Key Companies

• Moderna
• Nacuity Pharmaceuticals

Cytomegalovirus Pipeline Therapies

• mRNA-1647
• NP-3

Cytomegalovirus Pipeline Therapeutics Assessment

• By development stage
• By product type
• By route of administration
• By molecule type
• By MOA type

Scope of the Cytomegalovirus Pipeline Report 

• Coverage: Global
• Key Cytomegalovirus Companies: Moderna, and others
• Key Cytomegalovirus Pipeline Therapies: mRNA-1647, and others

Find out more about the Cytomegalovirus treatment options in development @ Cytomegalovirus Clinical Trials

Table of Contents

1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase  II)
7. Early Stage Products (Phase  I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Leading Reports by DelveInsight:

• Asthma Diagnostic Devices Market
• Chronic Obstructive Pulmonary Disease Treatment Devices Market
• Airway Management Devices Market
• Cough Assist Devices Market
• Pulse Oximeters Market
• Hemodialysis Catheter Devices Market
• Chronic Spontaneous Urticaria Market
• Gender Dysphoria Market
• Germany Healthcare Outlook
• Biopsy Devices Pipeline Insight
• Bacterial Conjunctivitis Market
• Infliximab Biosimilar Insight
• Eosinophilic Asthma Market
• Cushing Syndrome Market
• Functional Dyspepsia Market
• Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us

Kritika Rehani

info@delveinsight.com 

+1(919)321-6187